Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Merz Pharma GmbH & Co. KgaA - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Merz Pharma GmbH & Co. KgaA - Product Pipeline Review - 2014', provides an overview of the Merz Pharma GmbH & Co. KgaA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Merz Pharma GmbH & Co. KgaA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Merz Pharma GmbH & Co. KgaA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Merz Pharma GmbH & Co. KgaA's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Merz Pharma GmbH & Co. KgaA's pipeline products Reasons to buy - Evaluate Merz Pharma GmbH & Co. KgaA's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Merz Pharma GmbH & Co. KgaA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Merz Pharma GmbH & Co. KgaA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Merz Pharma GmbH & Co. KgaA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merz Pharma GmbH & Co. KgaA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Merz Pharma GmbH & Co. KgaA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Merz Pharma GmbH & Co. KgaA Snapshot 5 Merz Pharma GmbH & Co. KgaA Overview 5 Key Information 5 Key Facts 5 Merz Pharma GmbH & Co. KgaA - Research and Development Overview 6 Key Therapeutic Areas 6 Merz Pharma GmbH & Co. KgaA - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Merz Pharma GmbH & Co. KgaA - Pipeline Products Glance 10 Merz Pharma GmbH & Co. KgaA - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 Merz Pharma GmbH & Co. KgaA - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Merz Pharma GmbH & Co. KgaA - Early Stage Pipeline Products 13 Discovery Products/Combination Treatment Modalities 13 Merz Pharma GmbH & Co. KgaA - Drug Profiles 14 onabotulinumtoxinA 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 memantine hydrochloride 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 neramexane mesylate 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 MRZ-99030 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecule to Antagonise mGluR5 for CNS Disorders 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Merz Pharma GmbH & Co. KgaA - Pipeline Analysis 22 Merz Pharma GmbH & Co. KgaA - Pipeline Products by Target 22 Merz Pharma GmbH & Co. KgaA - Pipeline Products by Route of Administration 24 Merz Pharma GmbH & Co. KgaA - Pipeline Products by Molecule Type 25 Merz Pharma GmbH & Co. KgaA - Pipeline Products by Mechanism of Action 26 Merz Pharma GmbH & Co. KgaA - Recent Pipeline Updates 28 Merz Pharma GmbH & Co. KgaA - Dormant Projects 30 Merz Pharma GmbH & Co. KgaA - Discontinued Pipeline Products 31 Discontinued Pipeline Product Profiles 31 memantine hydrochloride 31 Merz Pharma GmbH & Co. KgaA - Company Statement 32 Merz Pharma GmbH & Co. KgaA - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables Merz Pharma GmbH & Co. KgaA, Key Information 5 Merz Pharma GmbH & Co. KgaA, Key Facts 5 Merz Pharma GmbH & Co. KgaA - Pipeline by Indication, 2014 7 Merz Pharma GmbH & Co. KgaA - Pipeline by Stage of Development, 2014 8 Merz Pharma GmbH & Co. KgaA - Monotherapy Products in Pipeline, 2014 9 Merz Pharma GmbH & Co. KgaA - Phase III, 2014 10 Merz Pharma GmbH & Co. KgaA - Phase II, 2014 11 Merz Pharma GmbH & Co. KgaA - Phase I, 2014 12 Merz Pharma GmbH & Co. KgaA - Discovery, 2014 13 Merz Pharma GmbH & Co. KgaA - Pipeline by Target, 2014 23 Merz Pharma GmbH & Co. KgaA - Pipeline by Route of Administration, 2014 24 Merz Pharma GmbH & Co. KgaA - Pipeline by Molecule Type, 2014 25 Merz Pharma GmbH & Co. KgaA - Pipeline Products by Mechanism of Action, 2014 27 Merz Pharma GmbH & Co. KgaA - Recent Pipeline Updates, 2014 28 Merz Pharma GmbH & Co. KgaA - Dormant Developmental Projects,2014 30 Merz Pharma GmbH & Co. KgaA - Discontinued Pipeline Products, 2014 31 Merz Pharma GmbH & Co. KgaA, Subsidiaries 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.